Frank W. Blixt

Frank W. Blixt

Auto-generated profile, based on publicly available information

Frank W. Blixt

Department of Clinical Sciences, Division of Experimental Vascular Research, Lund University, Lund, Sweden

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in The Journal of Pain
Verified
Journal Article
Closed access
SESajedeh Eftekhari
Sajedeh Eftekhari
KWKarin Warfvinge
Karin Warfvinge
FBFrank W. Blixt
Frank W. Blixt
LELars Edvinsson
Lars Edvinsson

10 August 2016 in Frontiers in Neural Circuits
Verified
Journal Article
Open access
AMAnna Matynia
Anna Matynia
ENEileen Nguyen
Eileen Nguyen
XSXiaoping Sun
Xiaoping Sun
FBFrank W. Blixt
Frank W. Blixt
SPSachin Parikh
Sachin Parikh
MGMichael B. Gorin
Michael B. Gorin
The ability of light to cause pain is paradoxical. The retina detects light but is devoid of nociceptors while the trigeminal sensory ganglia (TG) contain nociceptors but not photoreceptors. Melanopsin-expressing intrinsically photosensitive retinal ganglion cells (ipRGCs) are thought to mediate light-induced pain but recent evidence raises the possibility of an alternative light responsive pathway independent of the retina and optic nerve. Here, we show that melanopsin is expressed in both human and mouse TG neurons. In mice, they represent 3% of small TG neurons that are preferentially localized in the ophthalmic branch of the trigeminal nerve and are likely nociceptive C fibers and high-threshold mechanoreceptor Aδ fibers based on a strong size-function association. These isolated neurons respond to blue light stimuli with a delayed onset and sustained firing, similar to the melanopsin-dependent intrinsic photosensitivity observed in ipRGCs. Mice with severe bilateral optic nerve crush exhibit no light-induced responses including behavioral light aversion until treated with nitroglycerin, an inducer of migraine in people and migraine-like symptoms in mice. With nitroglycerin, these same mice with optic nerve crush exhibit significant light aversion. Furthermore, this retained light aversion remains dependent on melanopsin-expressing neurons. Our results demonstrate a novel light-responsive neural function independent of the optic nerve that may originate in the peripheral nervous system to provide the first direct mechanism for an alternative light detection pathway that influences motivated behavior.

1 March 2015 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
HAHilda Ahnstedt
Hilda Ahnstedt
MMMaryam Mostajeran
Maryam Mostajeran
FBFrank W Blixt
Frank W Blixt
KWKarin Warfvinge
Karin Warfvinge
SASaema Ansar
Saema Ansar
LELars Edvinsson
Lars Edvinsson
Sex differences are well known in cerebral ischemia and may impact the effect of stroke treatments. In male rats, the MEK1/2 inhibitor U0126 reduces ischemia-induced endothelin type B (ETB) receptor upregulation, infarct size and improves acute neurologic function after experimental stroke. However, responses to this treatment in females and long-term effects on outcome are not known. Initial experiments used in vitro organ culture of cerebral arteries, confirming ERK1/2 activation and increased ETB receptor-mediated vasoconstriction in female cerebral arteries. Transient middle cerebral artery occlusion (tMCAO, 120 minutes) was induced in female Wistar rats, with U0126 (30 mg/kg intraperitoneally) or vehicle administered at 0 and 24 hours of reperfusion, or with no treatment. Infarct volumes were determined and neurologic function was assessed by 6-point and 28-point neuroscores. ETB receptor-mediated contraction was studied with myograph and protein expression with immunohistochemistry. In vitro organ culture and tMCAO resulted in vascular ETB receptor upregulation and activation of ERK1/2 that was prevented by U0126. Although no effect on infarct size, U0126 improved the long-term neurologic function after experimental stroke in female rats. In conclusion, early prevention of the ERK1/2 activation and ETB receptor-mediated vasoconstriction in the cerebral vasculature after ischemic stroke in female rats improves the long-term neurologic outcome.

1 September 2016 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
ASAnna Steinberg
Anna Steinberg
SFSimona D Frederiksen
Simona D Frederiksen
FBFrank W Blixt
Frank W Blixt
KWKarin Warfvinge
Karin Warfvinge
LELars Edvinsson
Lars Edvinsson
Migraine and Cluster Headache (CH) are two primary headaches with severe disease burden. The disease expression and the mechanisms involved are poorly known. In some attacks of migraine and in most attacks of CH, there is a release of vasoactive intestinal peptide (VIP) originating from parasympathetic cranial ganglia such as the sphenopalatine ganglion (SPG). Patients suffering from these diseases are often deprived of effective drugs. The aim of the study was to examine the localization of the botulinum toxin receptor element synaptic vesicle glycoprotein 2A (SV-2A) and the vesicular docking protein synaptosomal-associated protein 25 (SNAP25) in human and rat SPG. Additionally the expression of the neurotransmitters pituitary adenylate cyclase activating polypeptide (PACAP-38), nitric oxide synthase (nNOS), VIP and 5-hydroxttryptamine subtype receptors (5-HT1B,1D,1F) were examined. SPG from adult male rats and from humans, the later removed at autopsy, were prepared for immunohistochemistry using specific antibodies against neurotransmitters, 5-HT1B,1D,1F receptors, and botulinum toxin receptor elements. We found that the selected neurotransmitters and 5-HT receptors were expressed in rat and human SPG. In addition, we found SV2-A and SNAP25 expression in both rat and human SPG. We report that all three 5-HT receptors studied occur in neurons and satellite glial cells (SGCs) of the SPG. 5-HT1B receptors were in addition found in the walls of intraganglionic blood vessels. Recent focus on the SPG has emphasized the role of parasympathetic mechanisms in the pathophysiology of mainly CH. The development of next generation’s drugs and treatment of cranial parasympathetic symptoms, mediated through the SPG, can be modulated by treatment with BoNT-A and 5-HT receptor agonists.

1 August 2017 in Experimental Eye Research
Verified
Journal Article
Closed access
FBFrank W. Blixt
Frank W. Blixt
ARAneta Radziwon-Balicka
Aneta Radziwon-Balicka
LELars Edvinsson
Lars Edvinsson
KWKarin Warfvinge
Karin Warfvinge

25 January 2018 in Acta Ophthalmologica
Verified
Journal Article
Open access
PDF file
FBFrank W. Blixt
Frank W. Blixt
KHKristian Agmund Agmund Haanes
Kristian Agmund Agmund Haanes
LOLena Ohlsson
Lena Ohlsson
ACAnders Tolstrup Christiansen
Anders Tolstrup Christiansen
KWKarin Warfvinge
Karin Warfvinge
LELars Edvinsson
Lars Edvinsson
Purpose: Even though retinal vascular changes following ischaemia have been poorly understood, the upregulation of vasoconstrictive endothelin‐1 (ET‐1) receptors (ETA/ETB) following global cerebral ischaemia has been described. The aim of this study was to investigate whether or not the MEK/ERK1/2 pathway is involved in the observed upregulation and whether specific MEK/ERK1/2 inhibitors U0126 and trametinib can prevent it.Methods: The aim was also to localize ETA and ETB receptors using immunohistochemistry in both fresh rat ophthalmic arteries and after 24‐hr organ culture and study the receptors functionally using myography. Pig retinal arteries also underwent 24‐hr organ culture to validate similar responses across species and the retinal vasculature.Results: Results showed that following organ culture there is a significant increase in ET‐1‐mediated vasoconstriction, in particular via the ETB receptor. Furthermore, immunohistochemistry revealed a clear increase in pERK in the smooth muscle cells of rat ophthalmic artery. U0126 and trametinib were successful in attenuating the functional vasoconstriction in both rat and pig, as well as restoring immunofluorescence of pERK to fresh levels and counteracting ETB expression in the smooth muscle cells of the rat ophthalmic artery.Conclusion: This is the first study to show that the MEK/ERK1/2 pathway in responsible for the increase in functional vasoconstriction via ET‐1 receptor in rat ophthalmic and pig retinal arteries. Furthermore, this study is the first to suggest a way of inhibiting and preventing such an increase. With these results, we suggest a novel approach in retinal ischaemia therapy.